Psychedelics re-engineered for potential use in the clinic

Gabriela Manzano-Nieves and Conor Liston ()

Nature, 2021, vol. 589, issue 7842, 358-359

Abstract: An analogue of the psychedelic drug ibogaine has been developed. The analogue mirrors ibogaine’s ability to treat addiction and depression in animal models, has fewer side effects and is much simpler to synthesize.

Keywords: Drug discovery; Neuroscience (search for similar items in EconPapers)
Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-020-03404-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:589:y:2021:i:7842:d:10.1038_d41586-020-03404-z

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-020-03404-z

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().